Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy. PURPOSE: This research study is measuring levels of TGF-beta in patients with epithelial cancers who are undergoing radiation therapy.

Interventions

  • RADIATION radiation therapy
  • PROCEDURE venipuncture

Study Locations (3)

Tennessee

  • Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville
  • Vanderbilt-Ingram Cancer Center at Franklin — Nashville
  • Vanderbilt-Ingram Cancer Center — Nashville

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2006-01
Est. Completion 2010-07

Sponsor

Vanderbilt-Ingram Cancer Center

143 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00897793

The ClinicalTrials.gov registry entry for NCT00897793 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 143 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which radiation therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00897793 reports 3 study locations spanning 1 distinct geographic area — top geographies include Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00897793 about?

NCT00897793 is a clinical study titled "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer". RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy. PURPOSE: This research study is ...

What is the current status of trial NCT00897793?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2006-01. Estimated completion is 2010-07.

What conditions does trial NCT00897793 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00897793?

The interventions under investigation include: radiation therapy (RADIATION), venipuncture (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00897793?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 143 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00897793 being conducted?

This trial has 3 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial